Loeillot Olivier sold $504K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 3,035 shares of REPLIGEN CORP (RGEN) at $165.90 ($0.50M total) on 2026-09-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Loeillot Olivier
Published Sep 8, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RGEN
Bearish
medium confidence
Mentioned
$RGEN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RGENBearishLow
01

Why it matters

The CEO's sale reduces his ownership, which may be interpreted as a negative signal, but the modest amount limits market reaction.

02

Market read

Primary disclosure of a CEO insider sale; modest size suggests limited trading impact but warrants monitoring.

03

What to watch

Potential 10b5‑1 plan execution and any upcoming earnings or clinical trial news could offset the sale impact.

Relevance 4/10Novelty 5/10Timing: post‑market filing on Sep 4 2026

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$RGENBearishMedium confidence
Context

CEO Loeillot Olivier sold 3,035 shares of Repligen at $165.90 each, reducing his stake to 48,369 shares.

Expected impact

Possible modest downside of 1-2% over the next few days.

Evidence & confidence

The sale size (~$0.5M) is modest for a mid-cap, but CEO involvement adds weight; market may react negatively.

Market effects

Minimal impact on the biotech sector; insider sales are common and not sector‑wide.

Limited to U.S. investors tracking Repligen.

Low; the filing does not affect broader markets.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook; price may remain stable.

Key entities

  • Repligen Corp.

    Biopharmaceutical company (ticker RGEN).

  • Loeillot Olivier

    Chief Executive Officer of Repligen.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENMed

Stifel reiterates Buy on Repligen stock, keeps $207 target

Stifel maintained a Buy rating on Repligen (NASDAQ:RGEN) with a $207 price target, citing upside from the Biolife acquisition and strong 2027 outlook. The stock has risen 51% in six months. Repligen reported Q3 2026 earnings of $0.53 per share, beating estimates, with revenue up 11% YoY. Canaccord Genuity kept a Hold rating with a $180 target.

$RGENHighAI 8/10

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENMed

Repligen Announces $1 Bln Convertible Notes Offering To Extend Debt Maturity

Repligen Corp. (RGEN) announced a $1 billion convertible notes offering due 2031. $541.4 million will exchange existing 2028 notes, while $458.6 million will be issued for cash. The new notes have a 20% premium conversion price. Proceeds will fund share repurchases, working capital, and potential acquisitions. The deal extends debt maturity and reduces interest expenses, benefiting EPS from 2026.